愛迪生氏症市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、藥物類別、分銷管道、地區和競爭格局分類，2021-2031年

全球愛迪生氏症市場預計將從 2025 年的 5.4623 億美元成長到 2031 年的 8.0968 億美元，複合年成長率為 6.78%。

這個市場主要集中於藥物治療，特別是皮質類固醇替代療法，例如Hydrocortisone和ludrocortisone，這些療法對於治療原發性腎上腺皮質功能不全至關重要。市場擴張的主要驅動力是全球自體免疫疾病發生率的上升，這類疾病需要患者終身接受荷爾蒙治療。此外，診斷篩檢系統的改善提高了即使在以往服務不足的地區，疾病檢出率也得到了提升。這導致確診患者群體顯著擴大，這對市場的持續發展和永續成長至關重要。然而，高誤診率和疾病本身的罕見性是阻礙市場擴張的主要因素。這些因素共同降低了開發創新藥物遞送系統的商業性獎勵。根據艾迪生病互助小組估計，2024 年的發病率較低，約為萬分之一，且市場分散，這往往導致關鍵治療性介入的延誤，並使先進製劑的投資難以收回。

市場促進因素

市場成長的主要驅動力是新型緩釋和長效荷爾蒙療法的持續研發。這些先進配方旨在模擬人體自然的皮質醇晝夜節律，從而提高原發性腎上腺皮質功能不全患者的治療依從性和臨床療效，並突破標準速釋皮質類固醇的生理限制。這些個人化療法的商業性成功顯而易見。 Eton Pharmaceuticals公司在2024年11月報告稱，其第三季產品銷售額成長了40%，達到980萬美元。這主要得益於市場對Alkindi Sprinkle（一種特效Hydrocortisone替代療法）的需求，凸顯了市場向精準給藥系統的轉變，尤其有利於兒童患者等弱勢群體。此外，罕見內分泌疾病治療研發投入的增加也正在拓展治療產品線。可靠的臨床檢驗支持了這一點，其中包括Neurocrine Biosciences公司於2024年5月發表的Efmody治療原發性腎上腺皮質功能不全成年患者的II期CHAMPAIN試驗的積極數據。儘管有這些創新，但該市場的特殊性（根據美國國立衛生研究院2024年3月的數據，其年發病率約為每10萬人0.6例）需要採用專門的開發方法。

市場挑戰

阻礙全球愛迪生氏症市場成長的主要障礙是誤診率高和疾病本身罕見性的雙重影響。疲勞和體重減輕等特異性症狀常導致醫護人員忽視腎上腺功能不全，造成診斷嚴重延遲。由於許多患者未被診斷和治療，診斷延誤顯著縮小了可主動開拓的市場，從而降低了對皮質類固醇療法的即時需求。此外，疾病的罕見性也使商業環境分散，降低了製藥公司投資研發新藥的經濟獎勵。為如此小的目標患者群體投入高昂的研發成本難以證明其合理性，阻礙了規模經濟的實現。根據美國國家罕見疾病組織（NORD）估計，到2024年，美國艾迪生病的盛行率約為十萬分之一，難以確保投資回報。這直接阻礙了先進治療方法的引入，並減緩了整體市場擴張。

市場趨勢

目前，兩大關鍵趨勢正在革新愛迪生氏症的治療。首先，新型緊急Hydrocortisone自動注射器的出現正在改變我們應對腎上腺危象（一種危及生命的併發症）的方式。這些裝置提供了一種簡化的、通常無需針頭的給藥機制，確保快速準確地輸送緊急藥物，從而提升了急性護理的安全性，優於傳統的管瓶和注射器給藥方式。商業化進程正在加速，例如，Crossject公司於2025年3月與Eton Pharmaceuticals公司合作開發ZENEOHydrocortisone自動注射器。其次，再生醫學的進步正在引領這一領域的發展，特別是基於生物印刷的組織療法。這種創新方法旨在透過移植生物工程組織來實現功能性癒合，從而恢復腎上腺的自然功能並模擬人體生理性的晝夜皮質醇節律，最終有可能使患者無需終身口服類固醇替代療法。臨床前檢驗，包括 Aspect Biosystems 於 2025 年 7 月發布的數據，顯示動物模型中腎上腺激素功能持續超過六個月，支持了這些解決方案對標準治療模型的顛覆性潛力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球愛迪生氏症市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 類型（原發性腎上腺皮質功能不全、續發性腎上腺皮質功能不全、三級腎上腺皮質功能不全）
  • 藥物分類（口服類固醇、皮質類固醇注射、鈉攝取量）
  • 銷售管道細分（醫院藥局、零售藥局、網路藥局）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美愛迪生氏症市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲愛迪生氏症市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區愛迪生氏症市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲愛迪生氏症市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲愛迪生氏症市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球愛迪生氏症市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Pfizer Inc.
• Merck & Co., Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Sanofi SA
• GlaxoSmithKline plc
• AbbVie Inc.
• Takeda Pharmaceutical Company Limited
• Boehringer Ingelheim International GmbH

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Addison's Disease Market is anticipated to grow from USD 546.23 Million in 2025 to USD 809.68 Million by 2031, achieving a Compound Annual Growth Rate (CAGR) of 6.78%. This market primarily encompasses pharmaceutical treatments, specifically corticosteroid replacement therapies like hydrocortisone and fludrocortisone, which are crucial for managing primary adrenal insufficiency. Market expansion is fundamentally propelled by the increasing global incidence of autoimmune disorders, which necessitate lifelong hormone management for affected individuals. Furthermore, improvements in diagnostic screening infrastructure are leading to enhanced detection rates in previously underserved areas. This effectively broadens the identified patient population, which is essential for ongoing market development and sustained growth. However, a significant barrier to this expansion is the high frequency of misdiagnosis coupled with the condition's inherent rarity, which collectively diminishes commercial incentives for the creation of innovative drug delivery systems. The low disease prevalence, estimated at approximately 1 in 10,000 individuals in 2024 by the Addison's Disease Self-Help Group, fragments the market, often delaying crucial therapeutic interventions and complicating the return on investment for advanced pharmaceutical formulations.

Market Driver

A key catalyst for market growth is the ongoing development of novel modified-release and long-acting hormone therapies. These advanced formulations are designed to emulate the body's natural circadian cortisol rhythm, thereby enhancing patient compliance and clinical outcomes in primary adrenal insufficiency management, moving beyond the physiological limitations of standard immediate-release corticosteroids. The commercial success of such tailored treatments is evident, with Eton Pharmaceuticals reporting a 40% increase in third-quarter product sales to $9.8 million in November 2024, largely driven by demand for Alkindi Sprinkle, a specialized hydrocortisone replacement therapy. This underscores a market shift towards precise delivery systems, particularly benefiting vulnerable populations like pediatric patients. Additionally, increasing R&D investment in rare endocrine disease therapeutics is expanding the treatment pipeline, supported by robust clinical validation, such as Neurocrine Biosciences' positive Phase 2 CHAMPAIN study data for Efmody in May 2024 for adults with primary adrenal insufficiency. Despite these innovations, the market's niche nature, characterized by an annual incidence of roughly 0.6 per 100,000 individuals as per NIH in March 2024, necessitates a specialized development approach.

Market Challenge

The primary obstacle hindering the growth of the Global Addison's Disease Market stems from the combined effect of high misdiagnosis rates and the condition's inherent rarity. Non-specific symptoms such as fatigue and weight loss frequently cause healthcare professionals to overlook adrenal insufficiency, leading to substantial delays in diagnosis. This diagnostic lag significantly reduces the actively addressable market, as many patients remain undiagnosed and untreated, thereby diminishing the immediate demand for corticosteroid therapies. Furthermore, the scarcity of the condition leads to a fragmented commercial landscape, which lessens the financial incentive for pharmaceutical companies to invest in developing new drug formulations. The substantial costs associated with R&D become difficult to justify for an exceptionally small target demographic, preventing the achievement of economies of scale. With an estimated prevalence of approximately 1 in 100,000 individuals in the United States in 2024, according to the National Organization for Rare Disorders, securing a viable return on investment becomes challenging, which directly impedes the introduction of advanced treatment options and slows overall market expansion.

Market Trends

Two significant trends are currently reshaping the management of Addison's disease. Firstly, the advent of novel emergency hydrocortisone auto-injectors is transforming how adrenal crises-a life-threatening complication-are managed. These devices offer simplified, often needle-free, delivery mechanisms, ensuring rapid and accurate administration of rescue medication, thereby enhancing acute care safety beyond conventional vial-and-syringe methods. Commercial progress is accelerating, exemplified by Crossject's collaboration with Eton Pharmaceuticals in March 2025 to finalize the ZENEO Hydrocortisone auto-injector. Secondly, the sector is pioneering advancements in regenerative medicine, specifically through bioprinted tissue therapeutics. This innovative approach aims for a functional cure by implanting bioengineered tissues capable of restoring natural adrenal function and mimicking the body's physiological circadian cortisol rhythm, potentially eliminating the need for lifelong oral steroid replacement. Preclinical validations, such as Aspect Biosystems' July 2025 data demonstrating sustained adrenal hormone function in animal models for over six months, underscore the disruptive potential of these solutions for standard care models.

Key Market Players

• Pfizer Inc.
• Merck & Co., Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Sanofi S.A.
• GlaxoSmithKline plc
• AbbVie Inc.
• Takeda Pharmaceutical Company Limited
• Boehringer Ingelheim International GmbH

Report Scope

In this report, the Global Addison's Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Addison's Disease Market, By Type

• Primary Adrenal Insufficiency
• Secondary Adrenal Insufficiency
• Tertiary Adrenal Insufficiency

Addison's Disease Market, By Drug Class

• Oral Corticosteroid
• Corticosteroid Injections
• Sodium Intake

Addison's Disease Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Addison's Disease Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Addison's Disease Market.

Available Customizations:

Global Addison's Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Addison's Disease Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Primary Adrenal Insufficiency, Secondary Adrenal Insufficiency, Tertiary Adrenal Insufficiency)
  • 5.2.2. By Drug Class (Oral Corticosteroid, Corticosteroid Injections, Sodium Intake)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Addison's Disease Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drug Class
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Addison's Disease Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drug Class
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Addison's Disease Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drug Class
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Addison's Disease Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drug Class
      • 6.3.3.2.3. By Distribution Channel

7. Europe Addison's Disease Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Drug Class
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Addison's Disease Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drug Class
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Addison's Disease Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drug Class
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Addison's Disease Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drug Class
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Addison's Disease Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Drug Class
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Addison's Disease Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Drug Class
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Addison's Disease Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Drug Class
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Addison's Disease Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drug Class
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Addison's Disease Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drug Class
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Addison's Disease Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drug Class
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Addison's Disease Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Drug Class
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Addison's Disease Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Drug Class
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Addison's Disease Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drug Class
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Addison's Disease Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drug Class
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Addison's Disease Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug Class
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Addison's Disease Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drug Class
      • 9.3.3.2.3. By Distribution Channel

10. South America Addison's Disease Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Drug Class
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Addison's Disease Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Drug Class
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Addison's Disease Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Drug Class
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Addison's Disease Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Drug Class
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Addison's Disease Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck & Co., Inc.
• 15.3. Novartis AG
• 15.4. Bristol-Myers Squibb Company
• 15.5. Eli Lilly and Company
• 15.6. Sanofi S.A.
• 15.7. GlaxoSmithKline plc
• 15.8. AbbVie Inc.
• 15.9. Takeda Pharmaceutical Company Limited
• 15.10. Boehringer Ingelheim International GmbH

16. Strategic Recommendations

17. About Us & Disclaimer